New genes and new insights from old genes: Update on alzheimer disease

CONTINUUM Lifelong Learning in Neurology

Volumn 19, Issue 2, 2013, Pages 358-371

  Ringman, John M ^a   Coppola, Giovanni ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN GENE; APOE GENE; FAMILIAL DISEASE; GENE; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; PRESENILIN 1 GENE; PRESENILIN 2 GENE; REVIEW; RISK FACTOR;

ADULT; AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; PRESENILINS;

EID: 84876383766     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000429179.21977.a1     Document Type: Review

References (84)

1. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):263-269.
2. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement 2012;8(2):131-168.
3. Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006;63(2):168-174.
4. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349(6311):704-706.
5. Wong CW, Quaranta V, Glenner GG. Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. Proc Natl Acad Sci USA 1985;82(24): 8729-8732.
6. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120(3):885-890.
7. Goldgaber D, Lerman MI, McBride OW, et al. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 1987;235(4791):877-880.
8. Kang J, Lemaire HG, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325(6106):733-736.
9. Tanzi RE, Gusella JF, Watkins PC, et al. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987;235(4791): 880-884.
10. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375(6534):754-760.
11. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2(8):864-870.
12. Benilova I, Karran E, De Strooper B. The toxic Aα oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012;15(3):349-357.
13. Mann DM, Yates PO, Marcyniuk B. Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol 1984;10(3): 185-207.
14. Ringman JM, Rao PN, Lu PH, Cederbaum S. Mosaicism for trisomy 21 in a patient with young-onset dementia: a case report and brief literature review. Arch Neurol 2008a; 65(3):412-415.
15. Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006;38(1):24-26.
16. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372(9634):216-223.
17. Mullan M, Tsuji S, Miki T, et al. Clinical comparison of Alzheimer's disease in pedigrees with the codon 717 Val-Ile mutation in the amyloid precursor protein gene. Neurobiol Aging 1993;14(5): 407-419.
18. Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008;71(2):85-92.
19. Basun H, Bogdanovic N, Ingelsson M, et al. Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol 2008;65(24):499-505.
20. Hendriks L, van Duijn CM, Cras P, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet 1992;1(3):218-221.
21. Levy E, Carman MD, Fernandez-Madrid IJ, et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990; 248(4959):1124-1126.
22. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012;488(7409):96-99.
23. De Strooper B, Saftig P, Craessaerts K, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998;391(6665):387-390.
24. Berezovska O, Lleo A, Herl LD, et al. Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. J Neurosci 2005;25(11): 3009-3017.
25. Sudoh S, Kawamura Y, Sato S, et al. Presenilin 1 mutations linked to familial Alzheimer's disease increase the intracellular levels of amyloid beta-protein 1-42 and its N-terminally truncated variant(s) which are generated at distinct sites. J Neurochem 1998;71(4):1535-1543.
26. Lopera F, Ardilla A, Martínez A, et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 1997;277(10):793-799.
27. Athan ES, Williamson J, Ciappa A, et al. A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. JAMA 2001; 286(18):2257-2263.
28. Murrell J, Ghetti B, Cochran E, et al. The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families. Neurogenetics 2006;7(4):277-279.
29. Lippa CF, Swearer JM, Kane KJ, et al. Familial Alzheimer's disease: site of mutation influences clinical phenotype. Ann Neurol 2000;48(3):376-379.
30. Filley CM, Rollins YD, Anderson CA, et al. The genetics of very early onset Alzheimer disease. Cogn Behav Neurol 2007;20(3): 149-156.
31. Cruchaga C, Haller G, Chakraverty S, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One 2012;7(2):e31039.
32. Houlden H, Baker M, McGowan E, et al. Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-beta concentrations. Ann Neurol 2000;48(5):806-808.
33. Lampe TH, Bird TD, Nochlin D, et al. Phenotype of chromosome 14-linked familial Alzheimer's disease in a large kindred. Ann Neurol 1994;36(3):368-378.
34. Joshi A, Ringman JM, Lee AS, et al. Comparison of clinical characteristics between familial and non-familial early onset Alzheimer's disease. J Neurol 2012; 259(10):2182-2188.
35. Jayadev S, Leverenz JB, Steinbart E, et al. Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain 2010;133(pt 4): 1143-1154.
36. Walker ES, Martinez M, Brunkan AL, Goate A. Presenilin 2 familial Alzheimer's disease mutations result in partial loss of function and dramatic changes in Abeta 42/40 ratios. J Neurochem 2005;92(2):294-301.
37. Ringman JM. What the study of persons at risk for familial Alzheimer's disease can tell us about the earliest stages of the disorder: a review. J Geriatr Psychiatry Neurol 2005; 18(4):228-233.
38. Acosta-Baena N, Sepulveda-Falla D, Lopera-Gómez CM, et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol 2011;10(3): 213-220.
39. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012; 11(12):1048-1056.
40. Fleisher AS, Chen K, Quiroz YT, et al. Florbetapir PET analysis of amyloid-α deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol 2012;11(12):1057-1065.
41. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367(9):795-804.
42. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278(16):1349-1356.
43. Kim J, Basak JM, Holtzman DM. The Role of apolipoprotein E in Alzheimer's disease. Neuron 2009;63(3):287-303.
44. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 2011;10(3):241-252.
45. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90(20):9649-9653.
46. Tiraboschi P, Hansen LA, Masliah E, et al. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 2004;62(11):1977-1983.
47. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67(1):122-131.
48. Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000;97(6):2892-2897.
49. Wisniewski T, Castaño EM, Golabek A, et al. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 1994;145(5):1030-1035.
50. Wahrle SE, Jiang H, Parsadanian M, et al. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 2005;280(5): 43236-43242.
51. Wahrle SE, Jiang H, Parsadanian M, et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 2008;118(2): 671-682.
52. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-α peptide clearance. Sci Transl Med 2011;3(89):89ra57.
53. Sharifov OF, Nayyar G, Garber DW, et al. Apolipoprotein E mimetics and cholesterol-lowering properties. Am J Cardiovasc Drugs 2011;11(6):371-381.
54. Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010;30(2):131-146.
55. Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-directed therapeutics rapidly clear α-amyloid and reverse deficits in AD mouse models. Science 2012;335(6075): 1503-1506.
56. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261(5123):921-923.
57. Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998;279(10):751-755.
58. Green RC, Roberts JS, Cupples LA, et al. Disclosure of APOE genotype for risk of Alzheimer's disease. New Engl J Med 2009; 361(3):245-254.
59. Lutz MW, Crenshaw DG, Saunders AM, Roses AD. Genetic variation at a single locus and age of onset for Alzheimer's disease. Alzheimers Dement 2010;6(2):125-131.
60. Roses AD, Lutz MW, Amrine-Madsen H, et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics 2010;10(5):375-384.
61. Chu SH, Roeder K, Ferrell RE, et al. TOMM40 poly-T repeat lengths, age of onset and psychosis risk in Alzheimer disease. Neurobiol Aging 2011;32(12):2328.e1-2328.e9.
62. Jun G, Vardarajan BN, Buros J, et al. Comprehensive search for Alzheimer disease susceptibility loci in the APOE region. Arch Neurol 2012:1-10.
63. Gerrish A, Russo G, Richards A, et al. The role of variation at APP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis 2012;28(2):377-387.
64. Bertram L, McQueen MB, Mullin K, et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007;39(1):17-23.
65. Hardy J, Singleton A. Genomewide association studies and human disease. N Engl J Med 2009;360(17):1759-1768.
66. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41(10):1088-1093.
67. Lambert J-C, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009;41(10): 1094-1099.
68. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011;43(5): 436-441.
69. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011;43(5):429-435.
70. Seshadri S, Fitzpatrick AL, Ikram AA, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010;303(18):1832-1840.
71. Nuutinen T, Suuronen T, Kauppinen A, et al. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 2009;61(2): 89-104.
72. Brouwers N, Van Cauwenberghe C, Engelborghs S, et al. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol Psychiatry 2012;17(2):223-233.
73. Baig S, Joseph SA, Tayler H, et al. Distribution and expression of picalm in Alzheimer disease. J Neuropathol Exp Neurol 2010;69(10):1071-1077.
74. Lambert J-C, Amouyel P. Genetics of Alzheimer's disease: new evidences for an old hypothesis? Curr Opin Genet Dev 2011;21(3):295-301.
75. Bertram L. Alzheimer's genetics in the GWAS era: a continuing story of ' replications and refutations'. Curr Neurol Neurosci Rep 2011;11(3):246-253.
76. Sullivan PF, Daly MJ, O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet 2012;13(8):537-551.
77. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009;461(7265):747-753.
78. Coppola G, Chinnathambi S, Lee JJ, et al. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet 2012;21(15):3500-3512.
79. Jonsson T, Stefansson H, Phe DSS, et al. Variant of TREM2 associated with the risk of Alzheimer's disease [published online ahead of print November 14, 2012]. N Engl J Med 2012. doi:10.1056/NEJMe1213157.
80. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease [published online ahead of print November 14, 2012]. N Engl J Med 2012. doi:10.1056/NEJMoa1211851.
81. Rovelet-Lecrux A, Legallic S, Wallon D, et al. A genome-wide study reveals rare CNVs exclusive to extreme phenotypes of Alzheimer disease. Eur J Hum Genet 2011; 20(6):613-617.
82. Jostins L, Barrett JC. Genetic risk prediction in complex disease. Hum Mol Genet 2011; 20(R2):R182-R188.
83. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491(7422):119-124.
84. Goldman JS, Hahn SE, Catania JW, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 2011;13(6):597-605.